Proceeds from the financing will be used to advance Neurogene's portfolio of multiple gene therapy programs into the clinic; accelerate investment in novel gene therapy product designs and Neurogene's technology platform addressing key limitations in conventional gene therapy, and build out Neurogene's state-of-the-art adeno-associated virus (AAV) vector GMP manufacturing capabilities.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

535 W 24th St. 5th Floor
New York, NY 10011
USA

Phone

877-237-5020

Website

www.neurogene.com

Email Address

[email protected]

Overview

Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Rachel McMinn

Chief Medical Officer

Effie Albanis

Chief Scientific Officer

Stuart Cobb

President

Christine Mikail

VP - Operations

Ricardo Jimenez

VP - Operations

Arvind Sreedharan

Browse more venture capital transactions:

Prev: 12/17/2020: Exo Therapeutics venture capital transaction
Next: 12/17/2020: Enveda Biosciences venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary